Fundraising FoxOban BioPharma
1 known investors
Find your way into Oban BioPharma
Sign up to find every way you can get introduced to Oban BioPharma
- Your email: who you already know at Oban BioPharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Oban BioPharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Oban Biopharma develops allosteric GPCR-targeted therapeutics for metabolic and CNS/neuropsychiatric diseases, using computational structural and chemotype analysis combined with AI-based druggability filters to identify drug candidates. Its pipeline focuses on allosteric modulators of clinically validated GPCR targets intended to offer efficacy with fewer side effects than traditional orthosteric drugs.
Founders & leadership
Investors · 1
Related companies · 2
Abalone BioAbalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning. The company uses large-scale biological measurement platforms and AI-powered sequence analysis to discover functional antibody drugs for pharmaceutical and biotechnology applications.
Abeona TherapeuticsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Companies working in the same space as Oban BioPharma.
Frequently asked questions
- What does Oban BioPharma do?
- Oban Biopharma develops allosteric GPCR-targeted therapeutics for metabolic and CNS/neuropsychiatric diseases, using computational structural and chemotype analysis combined with AI-based druggability filters to identify drug candidates. Its pipeline focuses on allosteric modulators of clinically validated GPCR targets intended to offer efficacy with fewer side effects than traditional orthosteric drugs.
- Who founded Oban BioPharma?
- Oban BioPharma was founded by Derek Chalmers.
- Who are Oban BioPharma's investors?
- Oban BioPharma's investors include Connecticut Innovations.